In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice

BMC Microbiology

R Paul Ross¹  Colin Hill¹  Paul D Cotter¹  Des Field²  Pat G Casey¹  Alicia Campion² 

[1] Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland;Department of Microbiology, University College Cork, Cork, Ireland

关键词: Nisin;    Mutagenesis;    Peptide engineering;    Bacteriocin;    Lantibiotic;    Antimicrobial;   

Others  :  1144474
DOI  :  10.1186/1471-2180-13-23

 received in 2012-10-10, accepted in 2013-01-30,  发布年份 2013

【 摘 要 】

Background

Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo.

Results

Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model.

More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 10⁵ cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen.

Conclusion

This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.

【 授权许可】

   
2013 Campion et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Rogers LA, Whittier EO: Limiting factors in the lactic fermentation. J Bacteriol 1928, 16:211-229.
• [2]Chen H, Hoover DG: Bacteriocins and their food applications. Comprehensive Rev Food Sci Food Safety 2003, 2:82-100.
• [3]Delves-Broughton J: Nisin and its uses as a food preservative. Food Technol 1990, 44:100-117.
• [4]Guinane CM, Cotter PD, Hill C, Ross RP: Microbial solutions to microbial problems; lactococcal bacteriocins for the control of undesirable biota in food. J Appl Microbiol 2005, 98:1316-1325.
• [5]de Vos WM, Kuipers OP, van der Meer JR, Siezen RJ: Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by Gram-positive bacteria. Mol Microbiol 1995, 17:427-437.
• [6]Sahl H, Jack R, Bierbaum G: Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur J Biochem 1995, 230:827-853.
• [7]Bierbaum G, Sahl HG: Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol 2009, 10:2-18.
• [8]Hsu ST, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM, van Nuland NA: The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 2004, 11:963-967.
• [9]Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG: Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 2001, 276:1772-1779.
• [10]Wiedemann I, Benz R, Sahl HG: Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. J Bacteriol 2004, 186:3259-3261.
• [11]Cotter PD, Hill C, Ross RP: Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci 2005, 6:61-75.
• [12]Piper C, Cotter PD, Ross RP, Hill C: Discovery of medically significant lantibiotics. Curr Drug Discov Technol 2009, 6:1-18.
• [13]Lawton EM, Ross RP, Hill C, Cotter PD: Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem 2007, 7:1236-1247.
• [14]New antibiotic compound enters phase I clinical trialhttp://www.wellcome.ac.uk/News/2011/News/WTVM053339.htm webcite
• [15]Foulston LC, Bibb MJ: Microbisporicin gene cluster reveals unusual features of lantibiotic biosynthesis in actinomycetes. Proc Natl Acad Sci U S A 2010, 107:13461-13466.
• [16]Jabes D, Brunati C, Candiani G, Riva S, Romano G, Donadio S: Efficacy of the new lantibiotic NAI-107 in experimental infections induced by MDR Gram-positive pathogens. Antimicrob Agents Chemother 2011, 55:1671-1676.
• [17]Smith L, Hillman J: Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr Opin Microbiol 2008, 11:401-408.
• [18]Piper C, Casey PG, Hill C, Cotter PD: The lantibiotic lacticin 3147 prevents systemic spread of Staphylococcus aureus in a murine infection model. Int J Microbiol 2012. 2012.
• [19]Severina E, Severin A, Tomasz A: Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J Antimicrob Chemother 1998, 41:341-347.
• [20]Brumfitt W, Salton MR, Hamilton-Miller JM: Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrob Chemother 2002, 50:731-734.
• [21]Piper C, Draper LA, Cotter PD, Ross RP, Hill C: A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2009, 63:546-551.
• [22]Piper C, Hill C, Cotter PD, Ross RP: Bioengineering of a nisin A-producing Lactococcus lactis to create isogenic strains producing the natural variants nisin F, Q and Z. Microb Biotechnol 2011, 4:375-382.
• [23]Coughlin R, Tikofsky L, Schulte H, Bennett G, Rejman J, Fisher D, Crabb J, Schukken Y: Lactation mastitistherapy with the nisin-based product MastOut: results of a 125-cow study. National Mastitis Council Annual Meeting 2004, 43:296-297.
• [24]Goldstein BP, Wei J, Greenberg K, Novick R: Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. J Antimicrob Chemother 1998, 42:277-278.
• [25]Taylor J, Hirsch AR, Mattick AT: The treatment of bovine streptococcal and staphylococcal mastitis with nisin. Vet Res 1949, 61:197-198.
• [26]Cao LT, Wu JQ, Xie F, Hu SH, Mo Y: Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows. J Dairy Sci 2007, 90:3980-3985.
• [27]Wu J, Hu S, Cao L: Therapeutic effect of nisin Z on subclinical mastitis in lactating cows. Antimicrob Agents Chemother 2007, 51:3131-3135.
• [28]De Kwaadsteniet M, Doeschate KT, Dicks LM: Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. Lett Appl Microbiol 2009, 48:65-70.
• [29]Brand AM, De Kwaadsteniet M, Dicks LMT: The ability of nisin F to control Staphylococcus aureus infection in the peritoneal cavity, as studied in mice. Lett Appl Microbiol 2010, 51:645-649.
• [30]van Staden AD, Brand AM, Dicks LMT: Nisin F-loaded brushite bone cement prevented the growth of Staphylococcus aureus in vivo. J Appl Microbiol 2012, 112:831-840.
• [31]Field D, Hill C, Cotter PD, Ross RP: The dawning of a ‘Golden era’ in lantibiotic bioengineering. Mol Microbiol 2010, 78:1077-1087.
• [32]Field D, O’Connor PM, Cotter PD, Hill C, Ross RP: The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. Mol Microbiol 2008, 69:218-230.
• [33]Carroll J, Field D, O’ Connor PM, Cotter PD, Coffey A, Hill C, Ross RP, O’ Mahony J: The gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Bioengineered Bugs 2010, 1:408-412.
• [34]Field D, Quigley L, O’Connor PM, Rea MC, Daly K, Cotter PD, Hill C, Ross RP: Studies with bioengineered nisin peptides highlight the broad-spectrum potency of nisin V. Microb Biotechnol 2010, 3:473-486.
• [35]Riedel CU, Monk IR, Casey PG, Morrissey D, O’Sullivan GC, Tangney M, Hill C, Gahan CGM: Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Appl Environ Microbiol 2007, 73:3091-3094.
• [36]Ingham A, Ford M, Moore RJ, Tizard M: The bacteriocin piscicolin 126 retains antilisterial activity in vivo. J Antimicrob Chemother 2003, 51:1365-1371.
• [37]Dabour N, Zihler A, Kheadr E, Lacroix C, Fliss I: In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes. Int J Food Microbiol 2009, 133:225-233.
• [38]Maher S, McClean S: Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Biochem Pharmacol 2006, 71:1289-1298.
• [39]Gupta SM, Aranha CC, Reddy KV: Evaluation of developmental toxicity of microbicide nisin in rats. Food Chem Toxicol 2008, 46:598-603.
• [40]Liu W, Hansen JN: Some chemical and physical properties of nisin, a small-protein antibiotic produced by Lactococcus lactis. Appl Environ Microbiol 1990, 56:2551-2558.
• [41]Rollema HS, Kuipers OP, Both P, de Vos WM, Siezen RJ: Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol 1995, 61:2873-2878.
• [42]Rouse S, Field D, Daly KM, O’Connor PM, Cotter PD, Hill C, Ross RP: Bioengineered nisin derivatives with enhanced activity in complex matrices. Microb Biotechnol 2012, 5:501-508.
• [43]Yuan J, Zhang ZZ, Chen XZ, Yang W, Huan LD: Site-directed mutagenesis of the hinge region of nisin Z and properties of nisin Z mutants. Appl Microbiol Biotechnol 2004, 64:806-815.
• [44]Field D, Begley M, O’Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C, Ross RP: Bioengineered nisin A derivatives with enhanced activity against both Gram positive and Gram negative pathogens. PLoS One 2012, 7:e46884.
• [45]Hagiwara A, Imai N, Nakashima H, Toda Y, Kawabe M, Furukawa F, Delves-Broughton J, Yasuhara K, Hayashi S-M: A 90-day oral toxicity study of nisin A, an anti-microbial peptide derived from Lactococcus lactis subsp. lactis, in F344 rats. Food Chem Toxicol 2010, 48:2421-2428.
• [46]Kuipers OP, Beerthuyzen MM, Siezen RJ, De Vos WM: Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity. Eur J Biochem 1993, 216:281-291.